Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
AECOPD is a major cause of hospital admission and mortality. They contribute to long-term
decline in lung function, physical capacity, and quality of life (QoL). RLS-0071 is a novel
peptide being developed for the treatment of AECOPD. This study is designed to evaluate the
safety and tolerability of RLS-0071 in the treatment of adults with moderate exacerbations of
COPD.